Drug-induced liver injury with autoimmune features

Seminars in Liver Disease

Volumn 34, Issue 2, 2014, Pages 194-204

  Delemos, Andrew S ^a   Foureau, David M ^a   Jacobs, Carl ^a   Ahrens, Will ^a   Russo, Mark W ^a   Bonkovsky, Herbert L ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

autoantibodies; autoimmune hepatitis; autoimmunity; drug induced liver injury

Indexed keywords

HYDRALAZINE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; AUTOANTIBODY; CYTOKINE; HLA ANTIGEN; URINARY TRACT ANTIINFECTIVE AGENT;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; LATENT PERIOD; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC ACTIVATION; PRIORITY JOURNAL; PROGNOSIS; TOXIC HEPATITIS; ADULT; AUTOIMMUNITY; BLOOD; CASE REPORT; COMPLICATION; DRUG HYPERSENSITIVITY; DRUG-INDUCED LIVER INJURY; FEMALE; GENETICS; HEPATITIS, AUTOIMMUNE; HYPERGAMMAGLOBULINEMIA; IMMUNOLOGY; LIVER; LIVER FUNCTION TEST; MALE; METABOLISM; PATHOLOGY; TIME FACTOR; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, URINARY; ANTIHYPERTENSIVE AGENTS; AUTOANTIBODIES; AUTOIMMUNITY; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; DRUG HYPERSENSITIVITY; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS, AUTOIMMUNE; HLA ANTIGENS; HUMANS; HYDRALAZINE; HYPERGAMMAGLOBULINEMIA; LIVER; LIVER FUNCTION TESTS; MALE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; TIME FACTORS; YOUNG ADULT;

EID: 84901763079     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1375959     Document Type: Article

References (64)

1. Boyer T. D., Manns M. P., Sanyal A. J. Zakim and Boyer's Hepatology - A Textbook of Liver Disease. 6th ed. Philadelphia, PA Elsevier: 2012
2. Surh C. D., Coppel R., Gershwin M. E. Structural requirement for autoreactivity on human pyruvate dehydrogenase-E2, the major autoantigen of primary biliary cirrhosis. Implication for a conformational autoepitope. J Immunol: 1990; 144 9 3367 3374 (Pubitemid 20146367)
3. Shimoda S., Nakamura M., Ishibashi H., et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology: 2003; 124 7 1915 1925 (Pubitemid 36666786)
4. Andrade R. J., Agúndez J. A., Lucena M. I., Martínez C., Cueto R., García-Martín E. Pharmacogenomics in drug induced liver injury. Curr Drug Metab: 2009; 10 9 956 970
5. Urban T. J., Shen Y., Stolz A., et al. Drug-Induced Liver Injury Network; DILIGEN; EUDRAGENE; Spanish DILI Registry; International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics: 2012; 22 11 784 795
6. Lawson J. A., Farhood A., Hopper R. D., Bajt M. L., Jaeschke H. The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. Toxicol Sci: 2000; 54 2 509 516 (Pubitemid 30185974)
7. Murphy E. J., Davern T. J., Shakil A. O., et al. Acute Liver Failure Study Group. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci: 2000; 45 3 549 553 (Pubitemid 30171932)
8. Alla V., Abraham J., Siddiqui J., et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol: 2006; 40 8 757 761 (Pubitemid 44350601)
9. García-Buey L., García-Monzón C., Rodriguez S., et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology: 1995; 108 6 1770 1777
10. Zhou S., Chan E., Duan W., Huang M., Chen Y. Z. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev: 2005; 37 1 41 213 (Pubitemid 40259715)
11. Ju C., Uetrecht J. P. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab: 2002; 3 4 367 377 (Pubitemid 34778003)
12. Russmann S., Jetter A., Kullak-Ublick G. A. Pharmacogenetics of drug-induced liver injury. Hepatology: 2010; 52 2 748 761
13. Pichler W. J., Beeler A., Keller M., et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int: 2006; 55 1 17 25
14. Kelly B. D., Heneghan M. A., Bennani F., Connolly C. E., O'Gorman T. A. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells. Am J Gastroenterol: 1998; 93 5 819 821 (Pubitemid 29063929)
15. Norcross M. A., Luo S., Lu L., et al. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS: 2012; 26 11 F21 F29
16. Bretscher P. A. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A: 1999; 96 1 185 190 (Pubitemid 29036074)
17. Czaja A. J., Cassani F., Cataleta M., Valentini P., Bianchi F. B. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology: 1996; 24 5 1068 1073 (Pubitemid 26365905)
18. Czaja A. J. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci: 2010; 55 8 2144 2161
19. Xiao X., Zhao P., Rodriguez-Pinto D., et al. Inflammatory regulation by TLR3 in acute hepatitis. J Immunol: 2009; 183 6 3712 3719
20. Imaeda A. B., Watanabe A., Sohail M. A., et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest: 2009; 119 2 305 314
21. Kubes P., Mehal W. Z. Sterile inflammation in the liver. Gastroenterology: 2012; 143 5 1158 1172
22. Aithal G. P., Ramsay L., Daly A. K., et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology: 2004; 39 5 1430 1440 (Pubitemid 38569066)
23. Crispe I. N. The liver as a lymphoid organ. Annu Rev Immunol: 2009; 27 147 163
24. Li J., Zhu X., Liu F., et al. Cytokine and autoantibody patterns in acute liver failure. J Immunotoxicol: 2010; 7 3 157 164
25. Steuerwald N. M., Foureau D. M., Norton H. J., et al. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS ONE: 2013; 8 12 e81974
26. Sutherland A. P., Joller N., Michaud M., Liu S. M., Kuchroo V. K., Grusby M. J. IL-21 promotes CD8+ CTL activity via the transcription factor T-bet. J Immunol: 2013; 190 8 3977 3984
27. Ghabril M., Bonkovsky H. L., Kum C., et al. US Drug-Induced Liver Injury Network. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol: 2013; 11 5 558 564, e3
28. Russo M. W., Scobey M., Bonkovsky H. L. Drug-induced liver injury associated with statins. Semin Liver Dis: 2009; 29 4 412 422
29. de Jong H. J., Tervaert J. W., Saldi S. R., et al. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum: 2011; 41 3 373 381
30. Jiménez-Alonso J., Jaimez L., Sabio J. M., Hidalgo C., Leon L. Atorvastatin-induced reversible positive antinuclear antibodies. Am J Med: 2002; 112 4 329 330 (Pubitemid 34219454)
31. Lucena M. I., Kaplowitz N., Hallal H., et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol: 2011; 55 4 820 827
32. von Felden J., Montani M., Kessebohm K., Stickel F. Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfate. Int J Clin Pharmacol Ther: 2013; 51 3 219 223
33. Fontana R. J., Hayashi P., Bonkovsky H. L., et al. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci: 2013; 58 6 1766 1775
34. Moreno-Otero R., García-Buey L., García-Sanchez A., Trapero-Marugán M. Autoimmune hepatitis after long-term methotrexate therapy for rheumatoid arthritis. Curr Drug Saf: 2011; 6 3 197 200
35. Lucena M. I., Andrade R. J., Kaplowitz N., et al. Spanish Group for the Study of Drug-Induced Liver Disease. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology: 2009; 49 6 2001 2009
36. Björnsson E. S., Bergmann O. M., Björnsson H. K., Kvaran R. B., Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology: 2013; 144 7 1419 1425, e1-e3, quiz e19-e20
37. Chalasani N., Fontana R. J., Bonkovsky H. L., et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology: 2008; 135 6 1924 1934, e1-e4
38. Björnsson E., Talwalkar J., Treeprasertsuk S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology: 2010; 51 6 2040 2048
39. Lawrenson R. A., Seaman H. E., Sundström A., Williams T. J., Farmer R. D. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf: 2000; 23 4 333 349
40. Stricker B. H., Blok A. P., Claas F. H., Van Parys G. E., Desmet V. J. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology: 1988; 8 3 599 606
41. Teitelbaum J. E., Perez-Atayde A. R., Cohen M., Bousvaros A., Jonas M. M. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med: 1998; 152 11 1132 1136 (Pubitemid 28509394)
42. Ramakrishna J., Johnson A. R., Banner B. F. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol: 2009; 43 8 787 790
43. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol: 2009; 62 6 481 492
44. Appleyard S., Saraswati R., Gorard D. A. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Reports: 2010; 4 311
45. Hebert M. F., Roberts J. P. Endstage liver disease associated with nitrofurantoin requiring liver transplantation. Ann Pharmacother: 1993; 27 10 1193 1194 (Pubitemid 23321965)
46. Bourdi M., Gautier J. C., Mircheva J., et al. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug. Mol Pharmacol: 1992; 42 2 280 285 (Pubitemid 23026160)
47. Belloc C., Gauffre A., André C., Beaune P. H. Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis. Pharmacogenetics: 1997; 7 3 181 186 (Pubitemid 27290631)
48. Bartoli E., Massarelli G., Solinas A., Faedda R., Chiandussi L. Acute hepatitis with bridging necrosis due to hydralazine intake. Report of a case. Arch Intern Med: 1979; 139 6 698 699 (Pubitemid 10146372)
49. Itoh S., Ichinoe A., Tsukada Y., Itoh Y. Hydralazine-induced hepatitis. Hepatogastroenterology: 1981; 28 1 13 16 (Pubitemid 11184203)
50. Rodman J. S., Deutsch D. J., Gutman S. I. Methyldopa Hepatitis. A report of six cases and review of the literature. Am J Med: 1976; 60 7 941 948
51. Suzuki A., Brunt E. M., Kleiner D. E., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology: 2011; 54 3 931 939
52. Heurgué-Berlot A., Bernard-Chabert B., Diebold M. D., Thiéfin G. Drug-induced autoimmune-like hepatitis: a case of chronic course after drug withdrawal. Dig Dis Sci: 2011; 56 8 2504 2505, author reply 2505
53. Czaja A. J. Drug-induced autoimmune-like hepatitis. Dig Dis Sci: 2011; 56 4 958 976
54. Davern T. J., Chalasani N., Fontana R. J., et al. Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology: 2011; 141 5 1665 1672, e1-e9
55. Manoussakis M. N., Tzioufas A. G., Silis M. P., Pange P. J., Goudevenos J., Moutsopoulos H. M. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol: 1987; 69 3 557 565 (Pubitemid 17125559)
56. Manns M. P., Czaja A. J., Gorham J. D., et al. American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology: 2010; 51 6 2193 2213
57. Gleeson D., Heneghan M. A.; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut: 2011; 60 12 1611 1629
58. Czaja A. J. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther: 2013; 38 4 343 364
59. Manns M. P., Woynarowski M., Kreisel W., et al. European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology: 2010; 139 4 1198 1206
60. Soloway R. D., Summerskill W. H., Baggenstoss A. H., et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology: 1972; 63 5 820 833
61. Czaja A. J., Wolf A. M., Baggenstoss A. H. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology: 1981; 80 4 687 692 (Pubitemid 11137747)
62. Lüth S., Herkel J., Kanzler S., et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol: 2008; 42 8 926 930
63. Amit G., Cohen P., Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J: 2002; 4 3 184 186 (Pubitemid 34624691)
64. Paiva L. A., Wright P. J., Koff R. S. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol: 1992; 87 7 891 893